If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...

The applications are supported by data from the ongoing phase 3 AQUILA study (NCT03301220) of Darzalex Faspro as monotherapy for the treatment of adult patients with high-risk smoldering multiple ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

"We believe that there is significant potential with Nammi's immunocytokine technology in the treatment of multiple cancer types ... the US Food and Drug Administration (FDA) for multiple myeloma in ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on ACLX stock, giving a Buy rating on November 8. Daina ...

Paul Mescal’s mum has revealed that her Hollywood star son invited her doctor to the premiere of Gladiator II last week.

Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...

Speaking to Miriam O'Callaghan on RTE Radio 1's Sunday with Miriam, Paul's mum Dearbhla, who was diagnosed with Multiple ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

A new study finds that pathogenic germline variants (PGVs) in cancer predisposition genes like BRCA1 and BRCA2 increase the risk of multiple ...